Tenapanor
Phase 3Completed 0 watching 0 views this week📈 Rising
72
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Constipation Predominant Irritable Bowel Syndrome
Conditions
Constipation Predominant Irritable Bowel Syndrome
Trial Timeline
Mar 1, 2016 → Oct 1, 2017
NCT ID
NCT02727751About Tenapanor
Tenapanor is a phase 3 stage product being developed by Ardelyx for Constipation Predominant Irritable Bowel Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT02727751. Target conditions include Constipation Predominant Irritable Bowel Syndrome.
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06810167 | Phase 3 | Recruiting |
| NCT05995899 | Approved | Completed |
| NCT06203444 | Phase 1 | Completed |
| NCT05905926 | Phase 3 | Recruiting |
| NCT04549597 | Approved | Completed |
| NCT02727751 | Phase 3 | Completed |
Competing Products
20 competing products in Constipation Predominant Irritable Bowel Syndrome